PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), AND IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome

Health Physics

Volumn 106, Issue 1, 2014, Pages 7-20

  Plett, Paul Artur ^a   Chua, Hui Lin ^a   Sampson, Carol H ^a   Katz, Barry P ^a   Fam, Christine M ^b   Anderson, Lana J ^b   Cox, George N ^b   Orschell, Christie M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Bolder BioTechnology Inc   (United States)

Author keywords

biological factors; blood; bonemarrow; mice; modeling

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; MACROGOL DERIVATIVE; PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR, HUMAN; PEGYLATED GRANULOCYTE COLONY-STIMULATING FACTOR, HUMAN;

ACUTE RADIATION SYNDROME; ANIMAL; ARTICLE; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; FEMALE; HEMATOPOIESIS; HUMAN; MALE; MOUSE; PATHOPHYSIOLOGY; RADIATION EXPOSURE; SURVIVAL; YOUNG ADULT;

ACUTE RADIATION SYNDROME; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; INTERLEUKIN-11; MALE; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84889580850     PISSN: 00179078     EISSN: 15385159     Source Type: Journal    
DOI: 10.1097/HP.0b013e3182a4dd4e     Document Type: Article

References (52)

1. Abuchowski A, Kazo GM, Verhoest CR Jr., Van Es T, Kafkewitz D, Nucci ML, Viau AT, Davis FF. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 7: 175-186; 1984
2. Anno GH, Young RW, Bloom RM, Mercier Jr. Dose response relationships for acute ionizing-radiation lethality. Health Phys 84: 565-575; 2003
3. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, PanW, Xu ZX, ModiMW, Farid A, Berthold W, Graves M. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycolconjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12: 195-202; 2001
4. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96: 80-85; 2000
5. Casarett A. Radiation biology. Englewood, New Jersey: Prentice-Hall Inc; 1968
6. Chua HL, Plett PA, Sampson CH, Joshi M, Tabbey R, Katz BP, MacVittie TJ, Orschell CM. Long-term hematopoietic stem cell damage in a murine model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys 103: 356-366; 2012
7. Cox GN. Cysteine variants of Interleukin-11. US Patent Number 8,133,480; 2012
8. Cox GN. Methods of use for cysteine variants of human G-CSF. US Patent Number 8,455,434; 2013
9. Cox GN, Doherty DH. Method of preparing cysteine mutants of human recombinant GM-CSF. US Patent Number 8, 148,500; 2012
10. Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol 30: 513; 2002
11. Demetri GD. Hematopoietic growth factors: Current knowledge, future prospects. Current Problems in Cancer 16: 177-259; 1992
12. Doherty DH, Rosendahl MS, Smith DJ, Hughes JM, Chlipala EA, Cox GN. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocytemacrophage colony-stimulating factor. Bioconjug Chem 16: 1291-1298; 2005
13. Drouet M, Delaunay C, Grenier N, Garrigou P, Mayol JF, Herodin F. Cytokines in combination to treat radiationinduced myelosuppresssion: Evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys. Haematologica 93: 465-466; 2008
14. Drouet M, Mourcin F, Grenier N, Leroux V, Denis J, Mayol JF, Thullier P, Lataillade JJ, Herodin F. Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: Long-term follow-up of hematopoiesis. Blood 103: 878-885; 2004
15. Du XX, Neben T, Goldman S, Williams DA. Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: Acceleration of recovery of peripheral blood neutrophils and platelets. Blood 81: 27-34; 1993
16. Farese AM, CohenMV, Katz BP, Smith CP, Gibbs A, Cohen DM, MacVittie TJ. Filgrastim Improves Survival in Lethally Irradiated Nonhuman Primates. Radiation Research 179: 89-100; 2013
17. Farese AM, Cohen MV, Katz BP, Smith CP, Jackson W 3rd, Cohen DM, MacVittie TJ. A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management. Health Phys 103: 367-382; 2012
18. Franzke A, Piao W, Lauber J, Gatzlaff P, Konecke C, Hansen W, Schmitt-Thomsen A, Hertenstein B, Buer J, Ganser A. G-CSF as immune regulator in T cells expressing the G-CSF receptor: Implications for transplantation and autoimmune diseases. Blood 102: 734-739; 2003
19. Goldman SJ. Preclinical biology of interleukin 11: A multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 13: 462-471; 1995
20. Grahn D. Acute radiation response of mice from a cross between radiosensitive and radioresistant strains. Genetics 43: 835-843; 1958
21. Grahn D, Hamilton K. Genetic variation in the acute lethal response of four inbredmouse strains towhole body x-irradiation. Genetics 42: 189-198; 1957
22. Herodin F, Grenier N, Drouet M. Revisiting therapeutic strategies in radiation casualties. Exp Hematol 35: 28-33; 2007
23. Kaye JA. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 16 Suppl 2: 207-223; 1998
24. Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 263: 15064-15070; 1988
25. Lee HT, Park SW, Kim M, Ham A, Anderson LJ, Brown KM, D'Agati VD, Cox GN. Interleukin-11 protects against renal ischemia and reperfusion injury. Am J Physiol Renal Physiol 303: F1216-F1224; 2012
26. Lushbaugh C. Reflections on some recent progress in human radiobiology. In: Augenstein L, Mason R, Zelles M, eds. Advances in Radiation Biology. New York, NY: Academic Press; 1969: 277
27. MacVittie TJ, Farese AM, Jackson W, 3rd. Defining the full therapeutic potential of recombinant growth factors in the post radiation-accident environment: The effect of supportive care plus administration of G-CSF. Health Phys 89: 546-555; 2005
28. MacVittie TJ, Monroy RL, Patchen ML, Souza LM. Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. International Journal of Radiation Biology 57: 723-736; 1990
29. Masood N, Shaikh AJ, Memon WA, Idress R. Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: A case report and review of literature. Cases J 1: 418; 2008
30. Mayer P, Lam C, Obenaus H, Liehl E, Besemer J. Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. Blood 70: 206-213; 1987
31. Mayer P, Werner FJ, Lam C, Besemer J. In vitro and in vivo activity of human recombinant granulocyte-macrophage colonystimulating factor in dogs. Exp Hematol 18: 1026-1033; 1990
32. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA, Cohen A, Korach E, Ulich T, McNiece I, Lockbaum P, Miller-Messana MA, Gardner S, Hunt T, Schwab G. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27: 1724-1734; 1999
33. Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire J, Schaub R, Goldman SJ. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 81: 901-908; 1993
34. Neta R. Cytokines in radioprotection and therapy of radiation injury. Biotherapy 1: 41-45; 1988
35. Neta R, Oppenheim JJ, Douches SD. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colonystimulating factor. J Immunol 140: 108-111; 1988
36. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. International Journal of Radiation Oncology, Biology, Physics 22: 773-779; 1992
37. Plett PA, Sampson CH, Chua HL, Joshi M, Booth C, Gough A,Johnson CS, Katz BP, Farese AM, Parker J, MacVittie TJ,Orschell CM. Establishing a murine model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys 103: 343-355; 2012
38. Reynolds CH. Clinical efficacy of rhIL-11. Oncology (Williston Park) 14: 32-40; 2000
39. Rosendahl M, Doherty D, Smith D, Bendele A, Cox G. Sitespecific protein PEGylation: Application to cysteine analogs of recombinant human granulocyte colony-stimulating factor. BioProcess International 3: 52-62; 2005
40. Schlerman FJ, Bree AG, Kaviani MD, Nagle SL, Donnelly LH,Mason LE, Schaub RG,Grupp SA,Goldman SJ. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myel suppressed nonhuman primates. Stem Cells 14: 517-532; 1996
41. Schuening FG, Storb R, Goehle S, Graham TC, Appelbaum FR,Hackman R, Souza LM. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood 74: 1308-1313; 1989
42. Schuening FG, Storb R, Goehle S, Nash R, Graham TC, Appelbaum FR, Hackman R, Sandmaier BM, Urdal DL. Stimulation of canine hematopoiesis by recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 17: 889-894; 1989
43. Schwertschlag US, Trepicchio WL, Dykstra KH, Keith JC, Turner KJ, Dorner AJ. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 13: 1307-1315; 1999
44. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 91: 1310-1313; 1993
45. Sureda A, Valls A, Kadar E, Algara M, Ingles-Esteve J, Bigas A, Jaume M, Lacruz M, Tobajas LM, Rutllant M, Garcia J. A single dose of granulocyte colony-stimulating factor modifies radiation-induced death in B6D2F1 mice. Exp Hematol 21: 1605-1607; 1993
46. Van der Meeren A, Mouthon MA, Gaugler MH, Vandamme M, Gourmelon P. Administration of recombinant human IL11 after supralethal radiation exposure promotes survival in mice: Interactive effect with thrombopoietin. Radiat Res 157: 642-649; 2002
47. Van der Meeren A, Mouthon MA, Vandamme M, Squiban C, Aigueperse J. Combinations of cytokines promote survival of mice and limit acute radiation damage in concert with amelioration of vascular damage. Radiat Res 161: 549-559; 2004
48. Vriesendorp H, Van Bekkum D. Susceptibility to total-body irradiation. In: Broerse J, MacVitties T, eds. Response of Different Species to Total Body Irradiaton. Amsterdam: Martinus Nijhoff; 1984
49. Wadhwa M, Thorpe R. Haematopoietic growth factors and their therapeutic use. Thromb Haemost 99: 863-873; 2008
50. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): The first 10 years. Blood 88: 1907-1929; 1996
51. Yang L, Yang YC. Regulation of interleukin (IL)-11 gene expression in IL-1 induced primate bone marrow stromal cells. J Biol Chem 269: 32732-32739; 1994
52. Yuhas JM, Storer JB. The effect of age on two modes of radiation death and on hematopoietic cell survival in the mouse. Radiat Res 32: 596-605; 1967